Bhumandeep Kour

Dr. Bhumandeep Kour

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2023 in Current Genomics
Verified
Journal Article
Open access
PDF file
BKBhumandeep Kour
Bhumandeep Kour
NSNidhi Shukla
Nidhi Shukla
HBHarshita Bhargava
Harshita Bhargava
DSDevendra Sharma
Devendra Sharma
ASAmita Sharma
Amita Sharma
Prashanth N SuravajhalaPrashanth N Suravajhala
Prashanth N Suravajhala
Background: Currently, prostate-specific antigen (PSA) is commonly used as a prostate cancer (PCa) biomarker. PSA is linked to some factors that frequently lead to erroneous positive results or even needless biopsies of elderly people. Objectives: In this pilot study, we undermined the potential genes and mutations from several databases and checked whether or not any putative prognostic biomarkers are central to the annotation. The aim of the study was to develop a risk prediction model that could help in clinical decision-making. Methods: An extensive literature review was conducted, and clinical parameters for related comorbidities, such as diabetes, obesity, as well as PCa, were collected. Such parameters were chosen with the understanding that variations in their threshold values could hasten the complicated process of carcinogenesis, more particularly PCa. The gathered data was converted to semi-binary data (-1, -0.5, 0, 0.5, and 1), on which machine learning (ML) methods were applied. First, we cross-checked various publicly available datasets, some published RNA-seq datasets, and our whole-exome sequencing data to find common role players in PCa, diabetes, and obesity. To narrow down their common interacting partners, interactome networks were analysed using GeneMANIA and visualised using Cytoscape, and later cBioportal was used (to compare expression level based on Z scored values) wherein various types of mutation w.r.t their expression and mRNA expression (RNA seq FPKM) plots are available. The GEPIA 2 tool was used to compare the expression of resulting similarities between the normal tissue and TCGA databases of PCa. Later, top-ranking genes were chosen to demonstrate striking clustering coefficients using the Cytoscape- cytoHubba module, and GEPIA 2 was applied again to ascertain survival plots. Results: Comparing various publicly available datasets, it was found that BLM is a frequent player in all three diseases, whereas comparing publicly available datasets, GWAS datasets, and published sequencing findings, SPFTPC and PPIMB were found to be the most common. With the assistance of GeneMANIA, TMPO and FOXP1 were found as common interacting partners, and they were also seen participating with BLM. Conclusion: A probabilistic machine learning model was achieved to identify key candidates between diabetes, obesity, and PCa. This, we believe, would herald precision scale modeling for easy prognosis.

11 May 2023 in Diseases
Verified
Journal Article
Open access
PDF file
NSNidhi Shukla
Nidhi Shukla
BKBhumandeep Kour
Bhumandeep Kour
DSDevendra Sharma
Devendra Sharma
MVManeesh Vijayvargiya
Maneesh Vijayvargiya
TST. C. Sadasukhi
T. C. Sadasukhi
Prashanth N SuravajhalaPrashanth N Suravajhala
Prashanth N Suravajhala
Prostate cancer (PCa) is one of the most prevalent cancers among men in India. Although studies on PCa have dealt with genetics, genomics, and the environmental influence in the causality of PCa, not many studies employing the Next Generation Sequencing (NGS) approaches of PCa have been carried out. In our previous study, we identified some causal genes and mutations specific to Indian PCa using Whole Exome Sequencing (WES). In the recent past, with the help of different cancer consortiums such as The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC), along with differentially expressed genes (DEGs), many cancer-associated novel non-coding RNAs have been identified as biomarkers. In this work, we attempt to identify differentially expressed genes (DEGs) including long non-coding RNAs (lncRNAs) associated with signature pathways from an Indian PCa cohort using the RNA-sequencing (RNA-seq) approach. From a cohort of 60, we screened six patients who underwent prostatectomy; we performed whole transcriptome shotgun sequencing (WTSS)/RNA-sequencing to decipher the DEGs. We further normalized the read counts using fragments per kilobase of transcript per million mapped reads (FPKM) and analyzed the DEGs using a cohort of downstream regulatory tools, viz., GeneMANIA, Stringdb, Cytoscape-Cytohubba, and cbioportal, to map the inherent signatures associated with PCa. By comparing the RNA-seq data obtained from the pairs of normal and PCa tissue samples using our benchmarked in-house cuffdiff pipeline, we observed some important genes specific to PCa, such as STEAP2, APP, PMEPA1, PABPC1, NFE2L2, and HN1L, and some other important genes known to be involved in different cancer pathways, such as COL6A1, DOK5, STX6, BCAS1, BACE1, BACE2, LMOD1, SNX9, CTNND1, etc. We also identified a few novel lncRNAs such as LINC01440, SOX2OT, ENSG00000232855, ENSG00000287903, and ENST00000647843.1 that need to be characterized further. In comparison with publicly available datasets, we have identified characteristic DEGs and novel lncRNAs implicated in signature PCa pathways in an Indian PCa cohort which perhaps have not been reported. This has set a precedent for us to validate candidates further experimentally, and we firmly believe this will pave a way toward the discovery of biomarkers and the development of novel therapies.

4 September 2025 in Journal of Molecular Evolution
Verified
Journal Article
Closed access
PDF file
SKShaikh Kaleem
Shaikh Kaleem
UDUjwal Dahal
Ujwal Dahal
SDShivani Devi
Shivani Devi
BKBhumandeep Kour
Bhumandeep Kour
SKSharanpreet Kour
Sharanpreet Kour

26 June 2022 in World Journal of Clinical Cases
Verified
Journal Article
Open access
MRMadhusmita Rout
Madhusmita Rout
BKBhumandeep Kour
Bhumandeep Kour
SVSugunakar Vuree
Sugunakar Vuree
SLSajitha S Lulu
Sajitha S Lulu
KMKrishna Mohan Medicherla
Krishna Mohan Medicherla
Prashanth N SuravajhalaPrashanth N Suravajhala
Prashanth N Suravajhala
An emerging area of interest in understanding disease phenotypes is systems genomics. Complex diseases such as diabetes have played an important role towards understanding the susceptible genes and mutations. A wide number of methods have been employed and strategies such as polygenic risk score and allele frequencies have been useful, but understanding the candidate genes harboring those mutations is an unmet goal. In this perspective, using systems genomic approaches, we highlight the application of phenome-interactome networks in diabetes and provide deep insights. LINC01128, which we previously described as candidate for diabetes, is shown as an example to discuss the approach.

9 March 2025 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
BKBarkha Khilwani
Barkha Khilwani
BKBhumandeep Kour
Bhumandeep Kour
NSNidhi Shukla
Nidhi Shukla
SVSugunakar Vuree
Sugunakar Vuree
AAAbdul S. Ansari
Abdul S. Ansari
RSRenuka Suravajhala
Renuka Suravajhala
Long non-coding RNA (lncRNAs) are known to be implicated in pathogenesis of a broad spectrum of malignancies. These are found to have a significant role as signal transduction mediators in cancer signaling pathways. Prostate Cancer (PCa) is emerging with increasing cases worldwide even as advanced approaches in clinical diagnosis and treatment of PCa are still challenging to address. To enhance patient stratification, there is an indefatigable need to understand risk that can allow new approaches of treatment based on prognosis. While PCa is known to have mediated androgen receptor (AR) stimulation, the latter plays a critical role in regulating transcription of genes via nuclear translocation which in turn leads to response to androgens. LncRNAs have been implicated in developing clinical diagnostic and prognostic biomarkers in a broad spectrum of cancers. In our present study, 12 lncRNAs identified from clinical samples from our erstwhile PCa patients were docked with PCa and AR targeted 36 proteins. We identified three lncRNAs, viz. SCARNA10, NPBWR1, ANKRD20A9P are common between the targeted proteins and discern that SCARNA10 lncRNA could serve as a prognostic signature for PCa and AR biogenesis. We also sought to check the coding potential of interfacial residues associated with lncRNA docking sites.

28 December 2025 in Journal of High School Science
Verified
Journal Article
Open access
PDF file
SRShreya Ramesh
Shreya Ramesh
KMKarthik Mangu
Karthik Mangu
BKBhumandeep Kour
Bhumandeep Kour
Early cancer detection remains challenging due to the limited sensitivity and specificity of current diagnostics. Liquid biopsy offers a minimally invasive alternative, with circulating long non-coding RNAs (lncRNAs) emerging as promising biomarkers because of their stability in biofluids and roles in tumor progression. However, clinical translation is hindered by substantial pre-analytical and analytical variability, as well as biological heterogeneity that compromises reproducibility. This review examines factors affecting circulating lncRNA stability, detection, and interpretation, including sample handling, analytical bias, and inter-individual variability, and summarizes ongoing standardization efforts such as MIQE and MISEV2023 guidelines, consortium protocols, and emerging bioinformatic strategies, while highlighting persistent gaps. We extrapolate recent findings that selective lncRNA packaging into Extracellular Vesicles (EVs) may be regulated by RNA-Binding Proteins (RBPs), to propose that this mechanism may be potentially modulated by SUMOylation, leading to structured yet variable circulating lncRNA patterns. Since any single biomarker is unlikely to differentially translate these patterns, we suggest that analyzing individual exosomes and combinatorial lncRNA signatures—conceptualized as a multidimensional “SUMO-barcode”—using a combination of chip-based single-exosome profiling and AI-driven pattern recognition could improve reproducibility and enable clinically robust circulating lncRNA biomarkers for early cancer detection.